RxDoctor Payments DataLook up a doctor →

Diane George, MD

Rheumatology · Charlotte, NCNPI 1811130123

Payments from drug & device makers

$43,338in general payments, 2019–2025

Across 307 payments — averaging $141.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$28K
  • Johnson & Johnson$10K
  • Sobi, Inc$2K
  • AbbVie$526
  • UCB, Inc.$510
  • Novartis$450
  • plus $2K from 24 others

What the payments were for

  • Consulting fees$9,42057%
  • Travel & lodging$8415%
  • Food & beverage$5,95236%
  • Education$2121%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,338 in reported general payments places this provider in the 75th percentile of 210 rheumatology providers in North Carolina.

See all rheumatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,045,653
Medicare patients
423
Services billed
52,543

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept38$324,297
Humira(Cf) PenAdalimumab40$295,930
Gamunex-CImmune Globul G/Gly/Iga Avg 4612$152,419
Cosentyx Sensoready PenSecukinumab11$103,276
OtezlaApremilast21$100,975
KevzaraSarilumab13$55,553
Actemra ActpenTocilizumab16$37,794
Hydroxychloroquine Sulfate334$13,248
MethotrexateMethotrexate Sodium303$7,436
Sulfasalazine DrSulfasalazine81$5,591
Leflunomide68$3,152
Mycophenolate Mofetil32$2,687
Azathioprine36$2,657
Febuxostat11$2,139
Colchicine35$2,038

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$28,205$100,97521 claims
Scilex Pharmaceuticals Inc.Colchicine$16$2,03835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 210 rheumatology providers in North Carolina.

Other rheumatology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →